Dr. Jessica Meshman, MD

Dr. Meshman practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Meshman's NPI, 1679920086, was assigned on May 17, 2016. Dr. Meshman graduated from Vanderbilt University School Of Medicine in 2016. Dr. Meshman holds Florida license ME151484.

Dr. Meshman's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Meshman's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Meshman practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Meshman's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Meshman is board certified in radiation oncology by the American Board of Radiology. Dr. Meshman is licensed in Florida.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, lymphoma radiation and prostate cancer radiation among the conditions Dr. Meshman treats.

CMS data shows 552 Medicare services from Dr. Meshman across 11 procedure codes in 2024, for 116 Medicare patients. Medicare paid $41,348 for them.

CMS counts 116 Medicare patients who saw Dr. Meshman in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have cancer, and 75% have high cholesterol. 30% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Meshman's median patient age at 69, with 78% women.

In 2024, Dr. Meshman wrote 58 Medicare Part D claims for 32 patients. 76% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $163 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Meshman for performance year 2024, reported as part of a group. Dr. Meshman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Meshman as offering telehealth.

Dmand AI links 10 papers to Dr. Meshman, published from 2017 to 2025. 2025 was the busiest year, with 3. The most frequent topics are Brain Neoplasms, Magnetic Resonance Imaging and Glioblastoma. Dr. Meshman has published most often in Cancers (Basel). Dr. Meshman's most frequent co-authors are Gregory Azzam, MD, PhD, Eric Albert Mellon, MD, PhD and Macarena Ines De La Fuente, MD.

CMS Open Payments shows 7 general payments to Dr. Meshman from 6 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Ambu Inc. paid the most, $120.

Dr. Meshman graduated from Vanderbilt University School Of Medicine in 2016.

Dr. Meshman is in network with 10 carriers, including Elevance, Aetna and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.